


04-06-06

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

3

Application Number

10/662,594

Filing Date

09/15/2003

First Named Inventor

Arnold

Art Unit

1614

Examiner Name

Spivack

Attorney Docket Number

6-OXO

ENCLOSURES (Check all that apply)



Fee Transmittal Form



Fee Attached



Amendment/Reply



After Final



Affidavits/declaration(s)



Extension of Time Request



Express Abandonment Request



Information Disclosure Statement



Certified Copy of Priority Document(s)

Reply to Missing Parts/
Incomplete ApplicationReply to Missing Parts
under 37 CFR 1.52 or 1.53

Drawing(s)



Licensing-related Papers



Petition

Petition to Convert to a
Provisional ApplicationPower of Attorney, Revocation
Change of Correspondence Address

Terminal Disclaimer



Request for Refund



CD, Number of CD(s) _____



Landscape Table on CD



After Allowance Communication to TC

Appeal Communication to Board
of Appeals and InterferencesAppeal Communication to TC
(Appeal Notice, Brief, Reply Brief)

Proprietary Information



Status Letter

Other Enclosure(s) (please identify
below):

Return postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Maloney, Parkinson & Berns

Signature

Printed name

Michael Berns

Date

04/05/2006

Reg. No.

38,379

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature

Typed or printed name

Michael Berns

Date

04/05/2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number: 10/662,594

Filing Date: 09/15/2003

Applicant: Arnold

Application Title: Use of androst-4-ene-3, 6, 17-trione...

Examiner: Spivack

Mailed April 5, 2006

Assistant Commissioner of Patents

Washington, D.C. 20231

AMENDMENT

In response to the Notice mailed 01/05/06, Applicant submits the following amendment:

Applicant's Attorney has been unable to reach the Examiner by telephone to discuss the rejection.

Applicant acknowledges the studies of Morales and Suzuki referenced that show a reduction of testosterone levels with increased age, and variability in ratios of estradiol. The present invention could assist those with these types of problems.

A recent long-term study was conducted at Baylor University to show the effectiveness of 8 week cycles of 6-OXO brand supplements produced by the assignee. There were two groups in the study, one group receiving 300 mg per day and a second group receiving 600 mg per day. Each group took the 6-OXO brand supplements for 8 weeks during which blood samples were taken at intervals throughout the cycle and at 3 weeks after the completion of the cycle. The blood was